PDF(Pubmed)
Abstract：
The treatment of immune thrombocytopenia (ITP) is challenging and treatment outcomes depend on numerous unknown and patient-specific factors. Corticosteroids are the cornerstone of ITP treatment, but they are associated with many side effects. In this retrospective cohort study, treatment outcomes and treatment adherence in patients with ITP were investigated in 214 ITP patients from November 15, 2022 to March 15, 2023. Multinomial regression analysis models were used to identify predictive factors for treatment outcomes. A p value of less than 0.05 was considered statistically significant. Most study participants were female 161 (75.5%), and the majority 172 (80.4%) of them were taking prednisolone only. In terms of treatment adherence, 178 (83.2%) of the study participants adhered well to their ITP medications. The complete response rate at 3 months was 139 (65.0%). Predictive factors for partial response were increased negative impact of ITP on health-related quality of life (AOR = 1.221, 95% CI 1.096-1.360), being treated at Tikur Abessa Sepcialazed Hospital (AOR = 0.431, 95% CI 0.197-0.941) and the presence of heavy menstrual bleeding (AOR = 2.255, 95% CI 0.925-5.497) compared to patients with complete response. Hepatitis B virus-infected ITP patients (AOR = 0.052, 95% CI 0.004-0.621) were also a predictive factor for no response compared to complete response.
摘要：
免疫性血小板减少症（ITP）的治疗具有挑战性，治疗结果取决于许多未知和患者特异性因素。皮质类固醇是ITP治疗的基石,但是它们与许多副作用有关。在这项回顾性队列研究中，我们在2022年11月15日至2023年3月15日期间,对214例ITP患者的治疗结局和治疗依从性进行了调查.多项回归分析模型用于确定治疗结果的预测因素。小于0.05的p值被认为是统计学上显著的。大多数研究参与者是女性161（75.5％），大多数172人(80.4%)只服用泼尼松龙。在治疗依从性方面，178（83.2%）的研究参与者坚持他们的ITP药物。3个月时的完全缓解率为139（65.0％）。部分反应的预测因素是ITP对健康相关生活质量的负面影响增加（AOR=1.221，95％CI1.096-1.360），与完全缓解患者相比,在TikurAbessaSepcialazed医院接受治疗(AOR=0.431,95%CI0.197-0.941)且存在大量月经出血(AOR=2.255,95%CI0.925-5.497)。乙型肝炎病毒感染的ITP患者（AOR=0.052，95％CI0.004-0.621）也是无反应的预测因素。
